Therapeutic options in advanced prostate cancer: present and future (Q36713545)

From Wikidata

Jump to navigation Jump to search

scientific article published on January 2007

edit

Language	Label	Description	Also known as
English	Therapeutic options in advanced prostate cancer: present and future	scientific article published on January 2007

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17239317

retrieved

15 August 2017

review article

1 reference

stated in

Europe PubMed Central

title

Therapeutic options in advanced prostate cancer: present and future (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17239317

retrieved

15 August 2017

main subject

prostate cancer

1 reference

based on heuristic

inferred from title

author name string

Richard D Sowery

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17239317

retrieved

15 August 2017

Alan I So

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17239317

retrieved

15 August 2017

Martin E Gleave

series ordinal

3

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17239317

retrieved

15 August 2017

publication date

1 January 2007

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17239317

retrieved

15 August 2017

published in

Current urology reports

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17239317

retrieved

15 August 2017

volume

8

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17239317

retrieved

15 August 2017

issue

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17239317

retrieved

15 August 2017

page(s)

53-59

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17239317

retrieved

15 August 2017

cites work

Impact of hospital procedure volume on surgical operation and long-term outcomes in high-risk curatively resected rectal cancer: findings from the Intergroup 0114 Study

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS11934-007-0021-9

retrieved

21 January 2018

A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17239317

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17239317

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17239317

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2'-O-(2-methoxy)ethyl chemistry.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17239317

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radiation therapy and radio-nuclides for palliation of bone pain

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17239317

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bisphosphonate treatment inhibits the growth of prostate cancer cells

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17239317

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17239317

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Importance of continued testicular suppression in hormone-refractory prostate cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17239317

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combined androgen blockade: an update.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17239317

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intracellular levels of SGP-2 (Clusterin) correlate with tumor grade in prostate cancer.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17239317

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17239317

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17239317

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17239317

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17239317

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17239317

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17239317

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The endothelin axis: emerging role in cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17239317

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17239317

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17239317

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17239317

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17239317

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17239317

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17239317

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antisense therapy for cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17239317

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Escaping cell death: survival proteins in cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17239317

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17239317

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17239317

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Calcitriol in the treatment of prostate cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17239317

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ASCENT: the androgen-independent prostate cancer study of calcitriol enhancing taxotere

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17239317

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17239317

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Secondary hormonal manipulations in the management of advanced prostate cancer.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17239317

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

DOI

10.1007/S11934-007-0021-9

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17239317

retrieved

15 August 2017

PubMed publication ID

17239317

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17239317

retrieved

15 August 2017

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36713545&oldid=2199222191"